Loading…
Loading…
PETV does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PETV and 80,000+ other tickers.
See exactly how PETV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PETV and 80,000+ other tickers.
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
New Human Health Subsidiary to Advance Development of Innovative Biomaterial Technologies and Potential New Products for Human and Animal Health MINNEAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) ("PetVivo" or the "Company"), an emerging biomedical device company focused on the commercialization and development of innovative medical devices and therapeutics, announced today that its subsidiary, Cosmeta Corp.
PetVivo Holdings, Inc. (PETV) Q1 2027 Earnings Call Transcript
MINNEAPOLIS, MN, US, Aug. 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported financial and operational results for the first quarter of its fiscal year ended June 30, 2026.
MINNEAPOLIS, MN, US, Aug. 07, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), an emerging biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Friday, August 14, 2026 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2026.
Agreement Resolves All Outstanding Matters and Completes Transition of PrecisePRP ® Product Line MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc. (collectively "PetVivo" or the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, today announced that it has entered into a Termination and Settlement Agreement with VetStem, Inc., effective July 24, 2026. Under the agreement, the parties have terminated their Exclusive License and Supply Agreement relating to the PrecisePRP® product line, resolved all matters arising under the parties' prior Exclusive License and Supply Agreement, and established an orderly transition of the remaining PrecisePRP® inventory and related commercial activities.